NCT03791866

Brief Summary

The investigators aim to evaluate the roles of Th9/IL-9 in the mechanisms of early enteral nutrition (EEN) maintaining intestinal mucosal barrier in sepsis. The results of this study would lay the foundation for revealing the mechanisms of EEN improving immune imbalance of sepsis and provide a new idea to the early treatment of sepsis. In addition, the investigators also aim to evaluate the effects of different proportions of target total enteral nutrition on the prognosis of sepsis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable sepsis

Timeline
Completed

Started Oct 2018

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2018

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

December 21, 2018

Completed
13 days until next milestone

First Posted

Study publicly available on registry

January 3, 2019

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2019

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2020

Completed
Last Updated

January 3, 2019

Status Verified

December 1, 2018

Enrollment Period

1.2 years

First QC Date

December 21, 2018

Last Update Submit

December 31, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • 28-d mortality

    28 days

Secondary Outcomes (4)

  • Serum Th9 lymphocyte percentages

    7 days

  • Concentration of serum IL-9

    7 days

  • Concentration of serum iFABP

    7 days

  • Concentration of serum DAO

    7 days

Study Arms (3)

30% target total enteral nutrition

EXPERIMENTAL
Other: Nutrition

60% target total enteral nutrition

EXPERIMENTAL
Other: Nutrition

100% target total enteral nutrition

ACTIVE COMPARATOR
Other: Nutrition

Interventions

Enteral nutrition

100% target total enteral nutrition30% target total enteral nutrition60% target total enteral nutrition

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Clinical diagnosis of sepsis
  • Within 3 days of sepsis onset before ICU admission
  • No artificial nutrition (enteral or parenteral nutrition) were provided before ICU admission

You may not qualify if:

  • Ileus
  • Digestive tract hemorrhage
  • Inflammatory bowel disease
  • Abdominal hypertension (IAP \>25mmHg)
  • Cancer or chronic organ dysfunction (e.g., hepatic or renal dysfunction)
  • Malnutrition or immunodeficiency
  • Long-term use of hormones

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Nanjing First Hospital

Nanjing, Jiangsu, 210000, China

RECRUITING

Related Publications (1)

  • Sun JK, Zhou J, Sun XP, Shen X, Zhu DM, Wang X, Zhou SM, Mu XW. Interleukin-9 promotes intestinal barrier injury of sepsis: a translational research. J Intensive Care. 2021 May 3;9(1):37. doi: 10.1186/s40560-021-00550-y.

MeSH Terms

Conditions

Sepsis

Interventions

Nutritional Status

Condition Hierarchy (Ancestors)

InfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Nutritional Physiological PhenomenaDiet, Food, and NutritionPhysiological PhenomenaHealth StatusDemographyPopulation Characteristics

Study Officials

  • Jia-Kui Sun

    The First Affiliated Hospital with Nanjing Medical University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, CARE PROVIDER
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director

Study Record Dates

First Submitted

December 21, 2018

First Posted

January 3, 2019

Study Start

October 1, 2018

Primary Completion

December 31, 2019

Study Completion

June 30, 2020

Last Updated

January 3, 2019

Record last verified: 2018-12

Locations